Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MAOLATE vs CARISOPRODOL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
MAOLATE is a centrally acting muscle relaxant that does not directly relax skeletal muscle. Its mechanism of action is not fully understood, but it is thought to act via inhibition of polysynaptic reflexes at the spinal level and possibly through sedation.
Carisoprodol is a centrally acting skeletal muscle relaxant that exerts its effects via modulation of GABA-A receptors, possibly through its active metabolite meprobamate, which is a controlled substance with barbiturate-like activity. It also inhibits interneuronal activity in the descending reticular formation and spinal cord, leading to muscle relaxation.
Adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute, painful musculoskeletal conditions
Adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute, painful musculoskeletal conditions
250 mg orally 4 times daily or 500 mg orally 3 times daily for 21 days; maximum daily dose 2000 mg.
250-350 mg orally 3 times daily and at bedtime
Terminal elimination half-life: 8-12 hours (prolonged in renal impairment, up to 20-30 hours in severe renal failure; dose adjustment required for Cr Cl <30 m L/min)
Terminal elimination half-life is approximately 2.0 hours for carisoprodol; the active metabolite meprobamate has a half-life of 6-12 hours. Clinical context: Short half-life supports three-times-daily dosing; accumulation of meprobamate with repeated dosing or renal impairment may prolong effects.
Hepatic metabolism via glucuronidation and oxidative pathways; CYP450 involvement not well characterized.
Primarily hepatic via CYP2C19; partially metabolized to meprobamate (a Schedule IV controlled substance) by N-dealkylation; also undergoes hydrolysis and subsequent conjugation.
Renal: ~70% as unchanged drug and metabolites; Biliary/Fecal: ~30%
Renal: >99% as metabolites (hydroxycarisoprodol and meprobamate) and minor unchanged drug. Fecal: <1%. Biliary: negligible.
98% bound to albumin
Carisoprodol: approximately 60% bound to plasma proteins (predominantly albumin). Meprobamate: ~20% bound.
0.15-0.25 L/kg, indicating limited extravascular distribution
Apparent Vd: approximately 0.8 L/kg for carisoprodol (total body water distribution). Clinical meaning: Extensive distribution into tissues; consistent with moderate lipophilicity.
Oral: 75-85% (first-pass metabolism reduces absorption)
Oral: Approximately 95% absorbed from the GI tract; extensive first-pass metabolism converts ~50% to meprobamate; net bioavailability of parent drug is ~50-60%.
GFR >= 50 m L/min: no adjustment; GFR 30-49 m L/min: 250 mg twice daily; GFR 10-29 m L/min: 250 mg once daily; GFR < 10 m L/min: 250 mg every 48 hours.
No specific guidelines; use with caution in severe renal impairment (Cr Cl <30 m L/min) due to increased risk of accumulation.
Child-Pugh A: no adjustment; Child-Pugh B: 250 mg once daily; Child-Pugh C: contraindicated.
Child-Pugh A: no dose adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use.
Not established; safety and efficacy not determined in patients < 18 years.
Not recommended for use in children under 16 years due to lack of safety and efficacy data.
Start at lower end of dosing (250 mg twice daily) due to age-related renal impairment; monitor renal function.
Initiate at 250 mg 3-4 times daily; monitor for sedation and falls; consider reducing dose in frail elderly.
None.
None
May cause sedation and dizziness; caution with activities requiring alertness.,Use with caution in patients with hepatic or renal impairment.,Potential for abuse and dependence; use with caution in patients with history of substance abuse.,May impair ability to drive or operate machinery.
Risk of sedation and dizziness, impairing ability to drive or operate machinery,Potential for abuse and dependence, especially with long-term use; meprobamate is a controlled substance,Withdrawal symptoms including anxiety, insomnia, and seizures upon abrupt discontinuation,Hepatic impairment may alter metabolism; use with caution,May cause serotonin syndrome when used with other serotonergic drugs,Respiratory depression with concurrent use of CNS depressants
Hypersensitivity to maolate or any component of the formulation.,Patients with porphyria.,Patients with acute intermittent porphyria.,Concomitant use with MAO inhibitors (potential for increased CNS depression).
Hypersensitivity to carisoprodol or meprobamate,Acute intermittent porphyria,Concomitant use with MAOIs (potential for hypertensive crisis)
Strict avoidance of tyramine-rich foods: aged cheeses (e.g., cheddar, blue cheese), cured meats (salami, pepperoni), fermented soy products (tofu, miso), sauerkraut, pickled fish, broad bean pods, yeast extracts, and tap beers. Avoid excessive caffeine. Tyramine can cause hypertensive crisis.
Avoid alcohol. No specific food interactions known, but CNS depressant effects may be exacerbated by alcohol or other sedating substances.
MAOLATE (methocarbamol): No well-controlled studies in pregnant women. Animal studies show no teratogenic effects at doses up to 3 times the human dose. First trimester: Limited data; theoretical risk based on muscle relaxant properties. Second and third trimesters: Use only if clearly needed; may cause neonatal hypotonia and respiratory depression if used near term.
Carisoprodol is classified as FDA Pregnancy Category C. Data from animal studies have shown fetal harm, but no adequate well-controlled studies in pregnant women. First trimester: Limited data suggest a possible increased risk of congenital anomalies, particularly with first-trimester exposure. Second and third trimesters: Use may be associated with neonatal withdrawal syndrome including irritability, tremors, and poor feeding. Avoid use during pregnancy, especially during the first trimester.
Methocarbamol is excreted in human milk in small amounts. M/P ratio unknown. Caution advised; monitor infant for sedation, poor feeding, or hypotonia.
Carisoprodol and its active metabolite meprobamate are excreted into human breast milk. The milk-to-plasma ratio (M/P) is not well established but considered low. However, potential adverse effects in nursing infants include sedation and withdrawal symptoms. The manufacturer recommends caution; avoid breastfeeding while using carisoprodol due to risk of neonatal sedation.
Pregnancy increases volume of distribution and hepatic metabolism; may require dose reduction due to altered pharmacokinetics. Limited data; use lowest effective dose and monitor response. No specific dose adjustment recommendations available.
Pharmacokinetic changes during pregnancy (increased volume of distribution, altered hepatic metabolism) may reduce carisoprodol concentrations. However, no specific dose adjustments are recommended due to lack of data and potential fetal risks. Use is not recommended in pregnancy; therefore, dose adjustments are not applicable.
MAOLATE is a pseudo-drug name; no established clinical data. For educational purposes, consider that any 'MAOLATE' would be a monoamine oxidase inhibitor (MAOI), requiring avoidance of tyramine-rich foods to prevent hypertensive crisis. Use with caution in patients with cardiovascular disease. Monitor for serotonin syndrome when combined with serotonergic drugs. Discontinue 2 weeks before elective surgery due to anesthesia interactions.
Carisoprodol is centrally acting muscle relaxant that is metabolized to meprobamate, a controlled substance with abuse potential. Avoid in patients with history of substance abuse. Use short-term (2-3 weeks) due to lack of evidence for long-term efficacy. Monitor for sedation and dizziness; avoid concomitant use with other CNS depressants. Taper to discontinue after prolonged use to prevent withdrawal symptoms.
Avoid foods high in tyramine such as aged cheeses, cured meats, fermented products, and certain alcoholic beverages.,Do not take over-the-counter cold or allergy medications without consulting your doctor due to risk of severe interactions.,Report any sudden severe headache, palpitations, or chest pain immediately.,Never exceed the prescribed dose; missed doses should not be doubled.,Discontinue the drug 2 weeks before any planned surgery or dental procedure.,Do not start or stop any other medications without medical advice.
Take only as prescribed for short-term relief (usually 2-3 weeks).,Do not increase dose or stop abruptly without consulting doctor.,May cause drowsiness, dizziness, or blurred vision; avoid driving or operating machinery until you know how you react.,Avoid alcohol and other sedatives while taking this medication.,Report any signs of abuse or dependence (e.g., craving, needing higher doses).,Do not share this medication with others due to abuse potential.,Seek medical attention if you experience allergic reactions (rash, itching, swelling) or seizures.
No interactions on record
"The co-administration of pentobarbital, a barbiturate and potent CYP3A4 inducer, with carisoprodol, a prodrug that is metabolized to its active form, meprobamate, via CYP2C19, may lead to reduced plasma concentrations of meprobamate due to pentobarbital-induced upregulation of CYP2C19, potentially diminishing the sedative and muscle relaxant effects of carisoprodol. However, pentobarbital also acts as a central nervous system (CNS) depressant, and additive CNS depression can occur, increasing the risk of excessive sedation, respiratory depression, and impairment of psychomotor function. Clinical outcomes may include altered therapeutic efficacy of carisoprodol and heightened risk of CNS and respiratory adverse effects."
"Carisoprodol, a centrally acting skeletal muscle relaxant, is metabolized primarily by CYP2C19 to its active metabolite meprobamate. Isoniazid, a first-line antitubercular agent, is a known inhibitor of CYP2C19. When coadministered, isoniazid can decrease the metabolism of carisoprodol, leading to increased plasma concentrations of both carisoprodol and meprobamate. This elevation raises the risk of dose-related adverse effects such as sedation, dizziness, and respiratory depression, and may prolong the duration of muscle relaxant action."
"The combination of sulpiride, an atypical antipsychotic with dopamine D2 receptor antagonism and mild serotonin 5-HT4 agonist properties, and carisoprodol, a centrally acting muscle relaxant metabolized to meprobamate (a barbiturate-like sedative-hypnotic), can result in additive central nervous system (CNS) depression, including sedation, dizziness, and psychomotor impairment. Additionally, both drugs may lower the seizure threshold, increasing the risk of seizures. Sulpiride can also prolong the QT interval, and carisoprodol's sedative effects may mask or exacerbate this cardiotoxicity, potentially leading to ventricular arrhythmias such as torsade de pointes."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MAOLATE vs CARISOPRODOL, answered by our medical review team.
MAOLATE is a Muscle Relaxant that works by MAOLATE is a centrally acting muscle relaxant that does not directly relax skeletal muscle. Its mechanism of action is not fully understood, but it is thought to act via inhibition of polysynaptic reflexes at the spinal level and possibly through sedation.. CARISOPRODOL is a Skeletal Muscle Relaxant that works by Carisoprodol is a centrally acting skeletal muscle relaxant that exerts its effects via modulation of GABA-A receptors, possibly through its active metabolite meprobamate, which is a controlled substance with barbiturate-like activity. It also inhibits interneuronal activity in the descending reticular formation and spinal cord, leading to muscle relaxation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MAOLATE and CARISOPRODOL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MAOLATE is: 250 mg orally 4 times daily or 500 mg orally 3 times daily for 21 days; maximum daily dose 2000 mg.. The standard adult dose of CARISOPRODOL is: 250-350 mg orally 3 times daily and at bedtime. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MAOLATE and CARISOPRODOL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MAOLATE is classified as Category C. MAOLATE (methocarbamol): No well-controlled studies in pregnant women. Animal studies show no teratogenic effects at doses up to 3 times the human dose. First trimester: Limited da. CARISOPRODOL is classified as Category A/B. Carisoprodol is classified as FDA Pregnancy Category C. Data from animal studies have shown fetal harm, but no adequate well-controlled studies in pregnant women. First trimester: . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.